NCT04964440 is a clinical trial of Pure-EP in Atrial Fibrillation Recurrent, sponsored by BioSig Technologies, Inc..

Who is sponsoring NCT04964440?

NCT04964440 is sponsored by BioSig Technologies, Inc..

What drugs are being tested in NCT04964440?

Interventions in NCT04964440: Pure-EP.

What condition does NCT04964440 study?

NCT04964440 studies Atrial Fibrillation Recurrent.

Is NCT04964440 still recruiting?

NCT04964440 is currently completed. Last updated 11 February 2022.

Last reviewed 2022-02-11 · How we verify

NCT04964440

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Redo AF Sub Study (of the Pure EP 2.0 Main Study)

Completed Last updated 11 February 2022

What this trial tests

trial testing Pure-EP in Atrial Fibrillation Recurrent in 20 participants. Completed in 29 January 2022.

Timeline

3 March 2021

Primary endpoint
20 July 2021

29 January 2022

Quick facts

Lead sponsor	BioSig Technologies, Inc.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	20
Start date	3 March 2021
Primary completion	20 July 2021
Estimated completion	29 January 2022
Sites	1 location across United States

Drugs / interventions tested

Pure-EP

Conditions studied

Atrial Fibrillation Recurrent — all drugs for Atrial Fibrillation Recurrent →

Sponsor

BioSig Technologies, Inc.

Who can join

18 and older, any sex, with Atrial Fibrillation Recurrent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a sub study of the Pure EP 2.0 trial. In a redo atrial fibrillation population, this study is designed to collect pulmonary vein signals pre and post ablation therapy, along with other non-pulmonary vein signals of interest during a redo ablation procedure. These signals are later evaluated for clinical relevance and impact on the procedure.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation Recurrent

Currently open trials in the same condition.

NCT06111443 — Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial F · Phase 2, PHASE3 · active not recruiting
NCT06253000 — Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium · NA · recruiting
NCT05266144 — Atrial Fibrillation Patients Treated With Catheter Ablation · recruiting

Other BioSig Technologies, Inc. trials

Trials by the same sponsor.

NCT04112433 — Novel Cardiac Signal Processing System · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04964440 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BioSig Technologies, Inc.
Last refreshed: 11 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04964440.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing